DRUG PRIOR AUTHORIZATION COMMITTEE MEETING
SEPTEMBER 18, 2009
205 JEFFERSON STREET JEFFERSON CITY, MO 65101

Committee Members Present
Gene Forrester, RPh
Steve Calloway, RPh
Conrad Balcer, DO
Pat Bryant, PharmD
Joe Parks, MD

Committee Members Absent
Henry Petry, DO, Chairman

MO HealthNet Staff Present

Rhonda Driver, RPh, Director Pharmacy
Jay Bryant-Wimp, RPh, Clinical Pharmacy
H. Diana Jones, Director Clinical Services
Lisa Clements, PhD, Clinical Director Psychology
Beth McQuaide, Special Assistant
Andrew Haslag, Fiscal Manager
Allison Lauf, RN
Mary Heet, RN
Jackie Hickman, Unit Supervisor
DJ Johnson, Program Development Specialist

Contractors Present
Jennifer Kemp-Cornelius, PharmD, ACS
Mark Roaseau, PharmD, MD, ACS
Sophie Backes Student Intern
Tom Beetem, RPh, IFOX
Morgan Sperry, UMKC, DIC
Meghan Williams, UMKC, DIC
Rick Pope, PharmD, First Health Services
Paula Boettler, Student Intern

Others in Attendance

John Viel, Genzyme	Eric Bake, Schreing-Plough	Don Larsen, Forest	Jeff Himmelberg, GSK
Bruce Cotogno, GSK	Vann Bennett, BI	John O'Malley, Genzyme	Sam Smothers, Med Immune
Carlos Palasciano, Hawthorne		Lisa Goetz, Med Immune	M. Patty Lasterm Genentech
D. Stubbs, Astra Zeneca	John Harris, Abbott	Barbara Belcher, Merck	Michael Jones, GSK
Grant Cale, BMS	Rob Kilo, Pfizer	Sheri Henderson, Pfizer	Phil King, Pfizer
Kristina Patel, Schering Plough	Ken Brier, Schering Plough	James Lieurance, Endo	Tracey Gasperi, UCB
Debbie King, Amgen	Kevin Doyles, UCB	Curt Griffen, UCB	Pam Sardo, Abbott

Matt Dull, Artia Solutions	Jeff Knappen, Allergan	Charles Dahmer, Amgen	Sonya Taylor, Novartis
Gamal Collier, Novartis	Diane Racicot, Strativa	Mark Gugliuzza, GSK	Brian Kellerman, GSK
William Dozier, Gilead	Todd Houldsworth, OMJ	Marcus Brickly, Actelion	Mitch Nagau, Actelion
Richard Mesquias, Lilly	Terry Rehmus, Centocor	Lon Lowry, Novartis	Ron Schnare, Shire
Joan Houstra, Centocor	Peggy Brand, Roche/Genentech	Matthew Stafford,	Ted Brandun, Alcon
Aaron Huwe, Gilead	William Dozier, Gilead	Melissa Penkalsla, Jordan Valley Comm Health	
R W Jackson, Praice Specialty Network		John Valenti, Sanofi	Gary Detmer, Taro
Mark Hagenhoff, Scicle	Carol Curtis, Astra Zeneca	Aaron Mays, Alcon	Annie Palmer, Taro
Deborah Mance, Biogen	Susan Zalenski, Johnson and Johnson		Victoria Lopez, Endo
James Osborne, GSK	Paige Nardi,	Kimberly Lynn, GSK	

Welcome, Introductions and Opening Remarks	Steven Calloway, RPh , Acting Chairman called the meeting to order at 10:00 a.m. Rhonda Driver, RPh, Director Pharmacy Program offered regrets from George L. Oestreich, PharmD, Deputy Division Director, who was unable to attend today's meeting. Student Interns, Paula Boettler and Sophie Backes were introduced. Meghan Williams, PharmD Candidate with the University of Missouri –Kansas City, Drug Information Center was introduced. Copies of correspondence received by the Division regarding products under review this quarter was shared with the Committee. Each letter was responded to by MHD.
Minutes Approval	Minutes from the June 16, 2008 meeting were approved as submitted,
Pharmacy Program Budget Update	Andrew Haslag, Fiscal Manager provided a summary of current budget activity. The Division is starting work on the budget for fiscal year 2011, which is due to the Governor's Office October 1st. It is expected that the Department /Division will be discussing efforts to save general revenue dollars. Ms. Driver provided an update on the carve out of pharmacy services from Managed Care. The carve out will add 270,000 to 280,000 lives to the fee-for-service pharmacy program and will become effective on October 1st. Ms. Driver noted that grandfathering and prior authorizations will be accepted. Ms Driver responded to questions from the Committee and audience including coverage of smoking cessation products, ED drugs, OTC drugs and other excluded drugs. The Committee agreed that the carve out was a positive step and looked forward to one pharmacy benefit for all MO HealthNet participants. The Committee will

	look forward to seeing cost comparison analysis. Ms. Driver updated the group on the status of the Request for Proposal (RFP) for a Preferred Drug List vendor. A contract extension was extended to First Health Services while the RFP was developed. The RFP is now out and due back the first of October.
DUR Report	Ms. Driver reported the DUR Board met July 22, 2009 and reviewed the Drug PA Committee's recommendations made at their June meeting. A quorum was not established and the Board met as a Committee of the Whole. A conference call was held in August at which all recommendations made were ratified.
Old Business	
Clinical Edits **Urinary Tract Antispasmodics**	●Discussion-Ms. Driver reviewed updates to the criteria document noting the addition of a new product Toviaz® to preferred status and new product Gelnique® Gel to non preferred status. ●Public Hearing-No comments were entered. ●Decision-Following this discussion the Committee vote to accept these changes to the current PDL edit. (See Roll Call Vote)
Implementation Schedule	An updated copy of the *Proposed Implementation Schedule for Edits* was included in the members' meeting packet and as a handout to all attendees. The schedule had been updated with all edits approved at the last quarter's meeting. This included the implementation following the annual review for one third of the PDL approved in June and July. The schedule may be found on the MO HealthNet Division's (MHD) Web-site at http://dss.missouri.gov/mhd/cs/pharmacy/imsched.pdf.
New Business	
New Drug Review	● Discussion- Drug monographs for new products reviewed during this quarter were available at http://www.heritage-info.com/mohealthnet. A listing of products detailing MHD's recommendations for open access, clinical edit, as a PDL product or for continued prior authorization was provided in the Members' meeting packet for discussion and action. This listing was also provided as a handout to all in attendance. Ms. Driver reviewed the recommendations and responded to Committee questions. Discussion ensued surrounding prenatal vitamins and the possibility of MAC pricing for the newer prenatal and nutritional vitamin products. at the suggestion of a Committee member. Ms. Driver stated the Division is looking at alternatives for handling this class.

	● Public Hearing-No comments were entered. ● Decision-Following this discussion the Committee voted to accept the new drug recommendations as presented. (See Roll Call Vote)
Synagis Edit Changes	●Discussion-Jay Bryant Wimp, RPh, Clinical Pharmacist reviewed proposed changes to the Synagis Clinical Edit. Mr. Bryant Wimp- noted recently published American Academy of Pediatrics (AAP) updated guidelines for the use of the product as well as Centers for Disease Control (CDC) and MO HealthNet hospitalization data were reviewed as the edit was being updated. Questions from the Committee were responded. ●Public Hearing-Nancy Goetz, PharmD, Med Immune and Melissa Penkalski, MSV, RN, FNP-PC, spoke in support of the product. Both expressed concerns at age limit changes for infants 32-35 week gestational age recommended by AAP. Ms. Goetz offered to supply a copy of a policy statement released by the AAP in August discussing these changes if the Committee requested. She commended Missouri for their choice to continue dosing infants after they reach the age of 90 days. Both speakers asked MHD to consider providing Synagis ® to infants less than 6 months of age at the onset of RSV season. ●Decision-Following these discussions the Committee approved the edit changes as submitted.
PDL Edits	Copies of proposed criteria for all classes under review were provided in the member's meeting packets as well as to all attending.
Ace Inhibitors	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change was being recommended for this class. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Ace Inhibitor/Diuretic Combination	● Discussion- Ms. Driver reviewed the criteria document noting no change to the current edit. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Roll Call Vote)

Ace Inhibitor/Calcium Channel Blocker Combinations	● Discussion- Ms. Driver summarized this document noting no changes other than the removal of a product, Lexxel®, which is no longer manufactured. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Alpha-Glucosidase Inhibitors	● Discussion- Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Alzheimer's Agents	● Discussion- Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status and approval criteria. No change to product coverage was being recommended with the exception of a new generic product, Galantamine, to non preferred status. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Angiotensin Receptor Blockers	● Discussion- Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change was being recommended for this class. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Angiotensin Receptor Blocker/Diuretic Combinations	● Discussion- Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change was being recommended for this class. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Antidiabetic Combination Agents	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. A new product, Prandimet® was added to non preferred status. Ms. Driver reminded members that the additional criteria surrounding heart failure and TZD products

	will continue with this edit. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Biguanides	● Discussion Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change was being recommended for this class which is a generics first edit. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Bone Ossification Suppression Agents/Calcitonins	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. Two new products, Skelid® and Calcitonin-Salmon Nasal, were recommended as non preferred status. All single ingredient Actonel® products (strengths) are now preferred status as well. ● Public Hearing- No comments were entered. ● Decision- Following review of the proposal the recommendation was approved as submitted. (See Roll Call Vote)
Direct Renin Inhibitor **Direct Renin Inhibitor/Combinations**	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting that all products were recommended for preferred status. Ms. Driver reminded the ARB step edit remains in place. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Electrolye Depleters	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. Changes were noted including the addition of a new product (Eliphos®) and the movement of Calcium Acetate Gel caps to non preferred status. Discussion surrounding the availability of Renagel® ensued. Ms. Driver noted the product was still available and remained in the preferred status for this therapeutic class. ● Public Hearing-John Beil with Genzyme provided background on the product Renvela® and the need for control of elevated phosphorus. He discussed the improved side effect profile of the product. He requested preferred status for

	the product. In response to a Committee question he stated that it is anticipated that Renagel® will discontinue in 2010. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Herpes Antivirals	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change was being recommended for this therapeutic class. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
DMARDS	● Discussion-Mr. Bryant Wimp reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. Cimzia®, Kineret®, and Remicade®, previously preferred agents, were being recommended for movement to non preferred status. A new product, Simponi® was added to the listing in non preferred status as well. Mr. Bryant Wimp clarified that the trial and failure criteria included the trial on methotrexate. Mr. Calloway reminded that non preferred products were available through clinical edit criteria not prior authorization. ● Public Hearing-Kevin Douglas, M.D. with UCB asked the Committee to consider Cimzia® for preferred status. Dr. Douglas discussed the predictability of the product, once per month dosing, dosing flexibility, ease of use because of design and packaging, safety profile and the approval for the treatment of Chron's Disease attained in April of this year. Terry Rehmus, PharmD, Centocor provided information on the unique formulation, once per month dosing, indications, and safety data on the product Simponi. Five phase three clinical trials were summarized. The Committee was asked to consider this product for preferred status. ● Decision- Following review of the proposal, the public comment and discussion surrounding utilization of the class the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Leukotriene Modifiers	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status Zyflo CR ® was moved to preferred status making all products in this therapeutic class

	preferred. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Lipotropics-Niacin Preparations	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change was being recommended for this therapeutic class. Simcor® is recommended for preferred status once a patient is compliant on extended release niacin therapy and compliant on simvastatin therapy. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented with the recommended change to reclassify the combo agent Advocor® to this class. (See Roll Call Vote)
Low Sedating Antihistamines	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change was recommended. Ms. Driver noted this is a OTC first edit. ● Public Hearing-No public comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Low Sedating Antihistamines/Decongestant Combinations	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No changes were recommended. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Macrolides Adult/Pediatric	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. This is a generics first edit. No change was being recommended for this therapeutic class. Members were reminded there is an existing edit for ready to use packs still in place. ● Public Hearing-no public comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the

	recommendation as presented. (See Roll Call Vote)
Meglitinides	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change was being recommended for this therapeutic class. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Multiple Sclerosis Agents	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change was recommended for this therapeutic class. All products in the therapeutic class were recommended for preferred status. Ms. Driver noted and oral product was about to enter the market in this therapeutic class. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Narcotics: Long Acting	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change was being recommended for this therapeutic class. Ms. Driver noted that generic Oxycontin (non preferred) was added to the listing as it is again available. Clinical edit criteria remain in place. Ms. Driver discussed availability issues with the product Duragesic®. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Intranasal Steroids	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No changes were recommended. ● Public Hearing-James Osborne, PharmD, GlaxoSmithKline touched on the attributes of Veramyst® that differentiate it from others in the class. Indications not limited to nasal symptoms were reviewed. Efficacy and safety were summarized. The consistency of improvement for ocular symptoms demonstrated by the product was stressed. A claims analysis study to determine treatment patterns was submitted for consideration. Dr. Osborne

	requested preferred status for the product. ● Decision- Following review of the proposal and public comment the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Ophthalmic Antihistamines	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. Ms. Driver noted the addition of Ketotifen OTC to preferred status and Ketotifen Rx to non preferred status. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Ophthalmic Mast Cell Stabilizers	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. Alamast® was moved to the non preferred side of the edit. It was suggested that MHD review the compliance model for this therapeutic class as well as ophthalmic antihistamines given their seasonal use. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Ophthalmic Qinolones	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status including the addition of a new product Besivance® and movement to Iquix ® to non preferred status. ● Public Hearing-A scheduled speaker for Vistakon on the product Iquix® deferred comment. No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Ophthalmic Prostaglandin Agonists	● Discussion-Ms. Driver reviewed the proposed criteria document noting that all products in the therapeutic class are preferred. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Oral Pulmonary Hypertension	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the

Agents	products recommended for preferred and non-preferred status. No change was being recommended for this therapeutic class. Ms. Driver pointed out the clinical criteria still in place for approval and also discussed Missouri's data that shows the state as on outlier compared to several other states in its utilization of this therapeutic class. Student Interns are researching and MO HealthNet will have updates in December as the non oral versions in this therapeutic class come up for review. Members suggested that MHD consider more stringent diagnostic criteria as they review this data. ● Public Hearing- Aaron Huwe, PharmD, Gilead reviewed a handout discussing the product Letaris®. Dr. Huwe discussed the clinical advantages of the product, efficacy, lack of drug-drug interaction, and LFT profile, dosing convenience and flexibility and safety. He requested Letaris® be considered for preferred status. ● Decision- Following review of the proposal and public comment the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Otic Quinolones	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change was being recommended for this therapeutic class other than the addition of a new product Cetraxal® to non preferred status. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Quinolones-Systemic	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change was being recommended for this therapeutic class. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
2nd Generation Sulfonylureas	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change was being recommended for this therapeutic class. The edit is a generics first edit. ● Public Hearing-No comments were entered.

	● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Serotonin Receptor Agonists (Triptans)	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. Changes included them movement of sumatriptan products to preferred status and Imitrex® and Relpax® to non preferred. The maximum daily dosing edit for these products remains in the edit. ● Public Hearing- Phil King, PharmD with Pfizer shared information on Relpax®. Dr. King summarized treatment alternatives, relevant guidelines, expected outcomes for the product, indications, efficacy, safety, and tolerability. Three randomized clinical studies were noted. Dr. King stated that the product was for episodic treatment of migraine headaches with the goal to minimize the use of these agents. Discussion ensued surrounding how this product would fit into the compliance model used by MHD. The Committee was asked to move the product back to preferred status. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented with modification to the compliance model for Relpax® to use claim count data. (See Roll Call Vote)
Thiazolidinediones	● Discussion-Ms. Driver reviewed the proposed criteria document. No change was being recommended for this therapeutic class. Heart failure risk clinical criteria will remain in place. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Topical Agents of Psoriasis	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change was recommended for this therapeutic class other than the addition of two new products Vectical® and Soriatane® CK to non preferred status. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Topical Retinoids	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. One new

	product (Epiduo®) to this therapeutic class was added to non-preferred status. Differin® was moved from preferred to non preferred status. Ms. Driver pointed out clinical criteria remains in place for approval. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Ulcerative Colitis Agents Oral and Rectal	● Discussion-Ms. Driver reviewed the proposed criteria documents. Noting the products recommended for preferred and non-preferred status. A new product (Apriso®) to the oral therapeutic class was added to preferred status while one new product (Asacol® HD) was added to the non preferred status. Dipentum® was recommended for movement to preferred status. Ms Driver pointed out clinical criteria remains in place for approval. A new product, SFRowasa®, Enema was added to non preferred status for the rectal agents. ● Public Hearing-Matt Dull, Alaven presented information on sulfate free SFRowasa® and discussed sulfite reactions. Studies were referenced. Safety and efficacy were discussed. Preferred status for the product was requested. ● Decision- Following review of the proposal and public comment the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Vaginal Antibiotics	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change to this therapeutic class was recommended. Ms Driver pointed out clinical criteria remains in place for approval. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Intranasal Antihistamines	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting all products were recommended for preferred status with the addition of Pantanase® and Astepro® to preferred status. Ms. Driver pointed out clinical criteria remains in place for approval. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Roll Call Vote)

Preferred Drug List Announcement	A handout of therapeutic categories for review and inclusion in the PDL during the next quarter was included in the meeting packet and to all meeting attendees. This listing will be posted to the Division's Web page a http://www.dss.mo.gov.mhd.. The posting will also be updated with the MHD recommendations prior to the December Drug Prior Authorization Committee meeting.
Program Utilization Information	A listing of the top 25 drugs for all quarters of 2009 and the months January and February of 2009 was provided for the Committee's Information. Copies were available to all attendees. This information was shared by product and paid claims rankings. Jennifer Kemp Cornelius, PharmD, ACS Healthcare provided a review of the edit in place for Skeletal Muscle Relaxants. Dr. Kemp Cornelius reviewed utilization data for January 2006 through June 2009 to provide the Committee with information regarding the effectiveness of the edit.
Clinical Edit Summary Report	An overview of clinical edit and prior authorization transactions was provided for the month of August 2009 was included in the meeting packet.
Call Center Statistics	A handout detailing pharmacy help desk call center activity was provided for all attending. Statistics for August 2009 were included. A report detailing CyberAccess™ activity from inception to present was also included.
Adjourn	The next meeting of the Committee is scheduled for December 17, 2009. A handout detailing meeting dates in 2010 was provided to all attendees. The Drug PA Committee went into executive session for the sole purpose of discussing individual participant specific medical information. At the conclusion of these discussions the group adjourned entertaining no further business, actions or motions. (See Roll Call Vote)

Roll Call Votes

Member	UTA	New Drug	Synagis	ACE/ACE Combo	ACE/CCB	Alpha Glucosidase	Alzheimers	ARBs ARB/Combo
Petry	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent
Forrester	**Second**	Yeah	**Second**	Yeah	Yeah	**Second**	Yeah	Yeah
Calloway	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah
Bryant	Yeah	**Second**	Yeah	**Second**	**Motion**	Yeah	**Second**	**Second**
Balcer	**Motion**	Yeah	**Motion**	**Motion**	**Second**	**Motion**	**Motion**	**Motion**
Parks	Yeah	**Motion**	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah

Member	Diabetic Combos	Biguanides	Bone Ossf	Direct Renin	Direct Renin/Combo	Electrolyte Depleters	Herpes Antiviral	DMARDS
Petry	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent
Forrester	**Motion**	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah	**Second**
Calloway	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah
Bryant	Yeah	**Motion**	**Motion**	**Second**	**Second**	**Motion**	**Motion**	**Motion**
Balcer	**Second**	**Second**	**Second**	**Motion**	**Motion**	**Second**	**Second**	Yeah
Parks	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah

Member	Leukotriene	Lipotropic Niacin	Low Sedate Antihistamine and Combos	Macrolides	Meglitinides	MS Agents	Narcotics Long Act
Petry	Absent	Absent	Absent	Absent	Absent	Absent	Absent
Forrester	**Motion**	Yeah	Yeah	**Second**	**Motion**	Yeah	**Motion**
Calloway	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah
Bryant	**Second**	**Second**	**Motion**	Yeah	Yeah	**Second**	Yeah
Balcer	Yeah	**Motion**	**Second**	**Motion**	**Second**	**Motion**	**Second**
Parks	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah

Member	Nasal Steroids	Opthl Antihistamin	Opthl Mast Cell	Opthl Prostaglandin	Oral PH Agents	Otic Quinolone	Quinolone Systemic	Sulfonylurea
Petry	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent
Forrester	**Motion**	Yeah	**Second**	Yeah	**Second**	**Second**	**Motion**	Yeah
Calloway	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah
Bryant	**Second**	**Motion**	Yeah	**Second**	Yeah	Yeah	**Second**	**Motion**
Balcer	Yeah	**Second**	**Motion**	**Motion**	**Motion**	**Motion**	Yeah	**Second**
Parks	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah

Member	**Triptans**	**TZD**	**Psoriasis Agents**	**Topical Retinoids**	**Closed Session**	**Adjourn**
Petry	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah
Forrester	**Motion**	Yeah	**Motion**	**Second**	Yeah	**Second**
Calloway	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah
Bryant	**Second**	**Second**	Yeah	Yeah	**Motion**	Yeah
Balcer	Yeah	**Motion**	**Second**	**Motion**	Yeah	Yeah
Parks	Yeah	Yeah	Yeah	Yeah	**Second**	**Motion**

Executive Session
September 17, 2009

Committee Members Present
Gene Forrester, RPh
Steve Calloway, RPh
Conrad Balcer, DO
Pat Bryant, PharmD
Joe Parks, MD
Committee Members Absent
Henry Petry

MO HealthNet Staff Present
George L. Oestreich, PharmD
Rhonda Driver, RPh
Jay Bryant-Wimp, RPh
Amy Woods
Beth McQuaide
Beth McQuaide
Allison Lauf, RN
Mary Heet, RN

Contractors Present
Jennifer Kemp-Cornelius, PharmD, ACS
Mark Roaseau, PharmD, MD, ACS
Sophie Backes Student Intern
Paula Boettler, Student Intern
Morgan Sperry, UMKC, DIC
Meghan Williams, UMKC, DIC
Rick Pope, PharmD, First Health Services

Minutes Review	**Minutes of the June 2009 Executive Session were approved as submitted.**
Case Reviews	**No cases were presented for review.**
Adjourn	**The meeting adjourned. (See Roll Call Votes)**